Please login to the form below
biologics
This page shows the latest biologics news and features for those working in and with pharma, biotech and healthcare.
Novartis agrees to help produce Roche’s repurposed COVID-19 drug
Novartis is fully committed to collaborating with Roche in offering our proven biologics production capabilities,” said Steffen Lang, head of Novartis technical operations and member of the Novartis executive committee.
Latest news
-
FDA approves new self-injection administration for Xolair
The FDA has approved the biologics licence application (BLA) for Xolair(omalizumab) prefilled syringe for self-injection across all approved indications in the US.
-
CanSinoBIO considers booster jab for COVID-19 vaccine
The efficacy of Chinese biotech company CanSino Biologics's (CanSinoBio) single-dose COVID-19 vaccine could decrease over time, according to the company’s chief scientific officer Zhu Tao.
-
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
Following this, BMS and bluebird re-filed the biologics licence application, saying that the new application provided further details about the chemistry, manufacturing and control (CMC) module of the submission to
-
Lilly reports positive data from its phase 3 ulcerative colitis trial
Mirikizumab also reduced symptoms in patients who had previously not responded to or stopped responding to biologic and/or Janus Kinase (JAK) inhibitor drugs.
-
AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population
In a statement, AZ said that tezepelumab is the first and only biologic medicine to consistently and significantly reduce AAER in a broad population of severe asthma patients, irrespective of baseline ... The unprecedented results from the NAVIGATOR
More from news
Approximately 21 fully matching, plus 603 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Other safety and manufacturing events such as three patient deaths in the high-dose arm of the Audentes’ ASPIRO trial and an FDA refusal to review the biologics licence application for
-
Growing evidence supports the important role of biosimilars in healthcare
In 2019, four of the top five prescription expenditures in the US were biologics and accounted for approximately $46 billion in expenditures. ... An estimated 1.2 million US patients could gain access to biologics by 2025 as the result of increasing
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
In comparison to many small-molecule medicines, biologics are often challenging to develop and costly to produce. ... patient access to more affordable, high-quality, and potentially life- changing biologic treatments.
-
Exploring the potential of eosinophils
Peter Howarth (pictured above), Global Clinical Scientific Lead for Biologics at GSK looks at the emerging science behind eosinophils and how it is helping to guide the company’s research and ... decisions. The eosinophils test is now well-established
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
in the manufacturing of complex biologic therapies, Amgen is leveraging this expertise to meet this growing need.
More from intelligence
Approximately 5 fully matching, plus 87 partially matching documents found.
Latest appointments
-
Ex-BMS exec jumps to Gilead to lead research group
That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
-
New hires at Crescendo, Healx and Galecto
The latest movers in pharma. Crescendo. Crescendo Biologics has appointed Kenji Hashimoto as its new chief medical officer, who joins Crescendo with over 15 years of experience in oncology and ... Kenji has considerable immuno-oncology expertise and an
-
New hires at FibroGen, Saniona and Turbine
Tuna currently serves as chief scientific officer at Adaptate Biotherapeutics, and has over 15 years of experience in biologics drug discovery and development.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... A champion for science and
-
BMS appoints new commercial leader, Davies joins Eisai and more
Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
More from appointments
Approximately 8 fully matching, plus 48 partially matching documents found.
Latest from PMHub
-
Integrated NHS finances: what do they mean for High Cost Drugs?
So, those with High Cost biologics are going to have to think carefully about their value proposition.
-
Living with psoriasis: a patient perspective
million[i]) received a biologic therapy in the UK in 2012.
-
Covid-19: how is it affecting prescribing patterns?
because as generic biologics get approved, use of branded biologics goes down and the arthritis pathway becomes cheaper to run. ... Yet, Gilenya aside, we found the medications trending upward were orally administered, which demonstrates a market
-
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen. ... Biobetters are enhanced versions of originator biologics, which potentially offer added value to
-
Innovative pricing and contracting options
3. For new entrants in the biologics space, adopting net pricing options is crucial since some US payers are volume sensitive and may prefer an older competitor drug that is clinically
More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- GSK discontinues two feladilimab trials in head and neck cancer
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- Live Webinar: Advancing Human Health Through Precise Measures of Movement, Cognition & Biometrics
- Live Webinar: How to Simplify Genetics & Raise Awareness Around Orphan Diseases
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
PMHub
integrated medhealth communication
imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
